Teva patents expiration
1. Austedo Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8524733 | TEVA | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Apr, 2031
(7 years from now) | |
| US9550780 | TEVA | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8524733 (Pediatric) | TEVA | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Oct, 2031
(8 years from now) | |
|
US9550780 (Pediatric) | TEVA | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(10 years from now) | |
| US11648244 | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(12 years from now) | |
| US11357772 | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(12 years from now) | |
| US10959996 | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(12 years from now) | |
| US11564917 | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(12 years from now) | |
| US11446291 | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(12 years from now) | |
|
US11446291 (Pediatric) | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(12 years from now) | |
|
US10959996 (Pediatric) | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(12 years from now) | |
|
US11564917 (Pediatric) | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(12 years from now) | |
|
US11357772 (Pediatric) | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(12 years from now) | |
|
US11648244 (Pediatric) | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(12 years from now) | |
| US11179386 | TEVA | Analogs of deutetrabenazine, their preparation and use |
Mar, 2038
(14 years from now) | |
|
US11179386 (Pediatric) | TEVA | Analogs of deutetrabenazine, their preparation and use |
Sep, 2038
(14 years from now) | |
| US11311488 | TEVA | Osmotic dosage forms comprising deutetrabenazine and methods of use thereof |
Jun, 2041
(17 years from now) | |
Drugs and Companies using DEUTETRABENAZINE ingredient
Market Authorisation Date: 17 February, 2023
Treatment: Treatment of tardive dyskinesia; A method of treating huntington's chorea
Dosage: TABLET, EXTENDED RELEASE;ORAL
AUSTEDO XR family patents
2. Azilect patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7815942 | TEVA | Rasagiline formulations of improved content uniformity |
Aug, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7572834 | TEVA | Rasagiline formulations and processes for their preparation |
Dec, 2026
(3 years from now) | |
Drugs and Companies using RASAGILINE MESYLATE ingredient
Market Authorisation Date: 16 May, 2006
Treatment: Treatment of parkinson's disease
Dosage: TABLET;ORAL
AZILECT family patents
3. Uzedy patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9717799 | TEVA | Drug-containing implants and methods of use thereof |
Jan, 2025
(1 year, 3 months from now) | |
| US9439905 | TEVA | Risperidone-containing implants and methods of use thereof |
Jan, 2025
(1 year, 3 months from now) | |
| US9895447 | TEVA | Drug-containing PLA implants and methods of use thereof |
Jan, 2025
(1 year, 3 months from now) | |
| US9925268 | TEVA | Drug-containing implants and methods of use thereof |
Jan, 2025
(1 year, 3 months from now) | |
| US10736965 | TEVA | Risperidone biodegradable implant |
Jan, 2025
(1 year, 3 months from now) | |
| US8802127 | TEVA | Risperidone-containing PLA:PGA implants and methods of use thereof |
Jan, 2025
(1 year, 3 months from now) | |
| US8741327 | TEVA | Method of maintaining therapeutic risperidone levels in a PLA:PLGA implant |
Nov, 2027
(4 years from now) | |
| US8221778 | TEVA | Drug-containing implants and methods of use thereof |
Nov, 2027
(4 years from now) | |
| US9023897 | TEVA | Biodegradable drug delivery compositions |
Apr, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product (NP) | Apr 28, 2026 |
Drugs and Companies using RISPERIDONE ingredient
Market Authorisation Date: 28 April, 2023
Treatment: Treatment of schizophrenia
Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
UZEDY family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic